News - BioPharm International

ADVERTISEMENT

News

Amgen's Psoriasis Candidate Bests Stelara in Head-to-Head Comparison

November 12, 2014

Amgen's Phase III candidate for the treatment of psoriasis was found to clear skin lesions better than Johnson & Johnson's Stelara.

France Agency Seeks Data from Roche on Use of Avastin in Macular Degeneration

November 7, 2014

ANSM wants company data on the benefits and risks of using Avastin over Lucentis in the treatment of wet age-related macular degeneration.

Perrigo Agrees to Acquire Omega Pharma for $4.5 Billion

November 6, 2014

The deal between the two companies will strengthen Perrigo's presence in Europe.

AstraZeneca Enters Collaboration with Pharmacyclics and Janssen to Test Hematologic Cancer Treatment

November 4, 2014

AstraZeneca announced a partnership with Pharmacyclics and Janssen for combination trials of MEDI4736 (AstraZeneca) with Imbruvica (Pharmacyclics and Janssen) for the treatment of hematologic cancers.

Amgen Requests FDA Require Certification of Compliance with Biosimilar Pathway

November 4, 2014

Amgen wants the regulatory agency to ensure biosimilar applicants follow the rules of the patent dispute resolution process delineated by the BPCIA.

M&A Activity in Pharma Still Strong Despite New Tax Rules

November 4, 2014

M&A transactions accounted for nearly $15 billion more this year than for the same period a year ago.

LabCorp to Acquire CRO Covance

November 3, 2014

LabCorp announced it will purchase contract research company Covance Inc. for approximately $6.1 billion in cash and stock.

BMS Enters Exclusive Agreement to Acquire Galecto's IPF Treatment

November 3, 2014

Bristol-Myers Squibb entered into an agreement with Galecto Biotech AB to gain exclusive rights to TD139, a novel inhaled inhibitor of galectin-3 for the treatment of idiopathic pulmonary fibrosis.

First Biosimilar Application Kicks Off Legal Battle

October 31, 2014

Amgen is suing Sandoz over Sandoz's biosimilar application for filgrastim.

ADVERTISEMENT

ADVERTISEMENT

Click here